Aim
Disease outcome in JIA patients after one year of treatment with TNFά therapy and their DNase I levels.
Methods
The study was performed in 25 JIA patients who donated paired serum samples prior and one year after continous etanercept therapy. Basic clinical data (six core set variables defined in ACR PEDI outcome score) were recorded along with alkalyne DNase I serum levels using the method where acid soluble nucleotides are determined spectrophotometrically at 260 nm. Treatment schedule of etanercept was 0,4mg/kg body weight subcutaneously twice weekly.
Results
JIA patients mean age was 14,7+/-4,22 and disease duration is 6,59+/-2,76. 
Conclusion
JIA patients with active disease have decreased DNase I levels. Our results indicate significant increase of DNase I in the sera of JIA patients after one year of anti TNFά therapy which was associated to the disease clinical improvement.
